Physician profile
Parween Moness
NPI 1326066119
$746.92
in general payments reported to CMS, 2019-2025
13 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.07 · 2021: $12.34 · 2023: $26.30 · 2024: $56.24 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.53 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $94.06 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $81.63 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $66.14 | 2025 | |
| Lilly USA, LLC | $53.81 | 2025 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $41.41 | 2020-2021 | |
| Exact Sciences Corporation | $39.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $39.75 | 2025 | Voquezna |
| Astellas Pharma US INC | $22.88 | 2024 | Veozah |
| Fisher & Paykel Healthcare INC | $21.66 | 2025 | Fisher & Paykel Healthcare |
| Pfizer INC. | $20.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $15.55 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parween Moness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.